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Abstract 
Vaccination against retroviruses is a challenge because of their ability to stably integrate into the host genome, 
undergo long‑term latency in a proportion of infected cells and thereby escape immune response. Since clearance 
of the virus is almost impossible once infection is established, the primary goal is to achieve sterilizing immunity. 
Besides efficacy, safety is the major issue since vaccination has been associated with increased infection or reversion 
to pathogenicity. In this review, we discuss the different issues that we faced during the development of an efficient 
vaccine against bovine leukemia virus (BLV). We summarize the historical failures of inactivated vaccines, the efficacy 
and safety of a live‑attenuated vaccine and the economical constraints of further industrial development.
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Background
Bovine leukemia virus (BLV) is the etiological agent of a 
B-lymphocyte proliferative disease of the bovine species 
[1–3]. Major symptoms are lymphoma (enzootic bovine 
leukemia or EBL) and persistent lymphocytosis (PL) 
[4]. Approximately one third of BLV-infected cows will 
develop PL while tumors affect 5–10% of animals after 
long latency periods (4–10  years). At the asymptomatic 
stage, BLV infection is associated with reduced milk pro-
duction [4], shortened longevity [5] and immune sup-
pression [6]. Because no obvious symptoms are observed 
in most animals, BLV has been neglected in many regions 
worldwide. BLV prevalence has nevertheless a major eco-
nomic impact according to recent prediction models [7]. 
Net benefits per cow of controlling BLV on farm is CAD 
1592 for a strategy of “test and cull”. The direct impact 
is also associated with trade restrictions of live animals 
or genetic material, resulting in limitations in the access 
to potential markets (e.g. export from South America to 
EU). Death as consequence of lymphosarcoma impacts 
straight on the production facilities, with major losses 
because of no milk production, no calve replacement and 
costs associated with treatment and anticipated slaugh-
ter. The reduction in prevalence of 15% per year results in 
a positive net benefit when continued over at least 2 years 
[8].
With the exception of the European Union (EU), the 
herd prevalence of BLV worldwide ranges between 30 
and 90% [8]. BLV has been eradicated from EU in the 
1980′s thanks to a very expensive strategy consisting of 
systematic testing and culling [9]. Eradication is thus effi-
cient but not cost-effective in highly prevalent regions. 
Another option is to create an independent internal facil-
ity with non-infected animals. This “test and segregate” 
strategy needs duplicated housing facilities and equip-
ment in strictly separated areas [10]. This approach has 
been mostly unsuccessful due to increased costs and fail-
ures in long-term commitment to the program. It is also 
possible to take biosafety and management measures in 
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agent. Testing and implementing best management strat-
egies is intensively laborious, needs strict adherence to 
rigorous implemented measures and is susceptible to 
environmental factors.
Because the virion is extremely unstable, BLV trans-
mission requires the transfer of an infected cell carrying 
a replication-competent provirus. Therefore, iatrogenic 
procedures (i.e. dehorning, ear tattooing, rectal palpation 
and use of infected needles) are likely the major routes 
of transmission. Experimental evidence and predictive 
models incriminate insects as potential vectors [11]. Fur-
thermore, BLV transmission can also occur intra utero 
by a still unknown mechanism (approximately 5% calves 
being infected at birth). Therefore, the efficacy of a “test 
and manage” strategy based on strict sanitary measures 
has been limited.
Since BLV replication is tightly controlled by a very effi-
cient immune response [12, 13], it should in principle be 
possible to select breeds that are less susceptible or even 
resistant to infection. Polymorphisms in major histocom-
patibility genes (MHC) genes have been associated with 
reduced proviral loads [14, 15]. However, genetic resist-
ance to BLV infection appears to be a complex mecha-
nism that is controlled by multiple genes. Although still 
unclear, the driving forces of MHC polymorphism selec-
tion may be driven by the virus itself but also by mecha-
nisms that avoid inbreeding. Pathogen-driven selection 
can be based on heterozygote advantage (overdomi-
nance) or frequency-dependent selection resulting from 
pathogen evasion of immune recognition [16–18]. Fur-
thermore, epigenetic mechanisms and environmental 
factors contribute to the outcome of infection. Therefore, 
it will be difficult to prioritize one allele over others as 
an absolute genetic selection marker for selecting BLV 
resistant breeds. Even more important, selection based 
on disease resistance may also have adverse effects on 
productivity traits.
Since the proviral loads are the best predictor of trans-
mission, another strategy would consist in using antiviral 
therapy. Valproic acid, a lysine deacetylase inhibitor, has 
been successfully used to reduce proviral loads and treat 
BLV-induced leukemia [19]. However, long-term treat-
ment with valproic acid is unable to eradicate the BLV 
reservoir and is associated with chemoresistance [20].
In this context, the availability of a safe and effi-
cient vaccine is probably the most suitable approach to 
decrease prevalence of BLV worldwide.
Why did many BLV vaccines fail?
The ideal vaccine should be safe and provide complete 
protection against BLV infection. It is still unclear why 
so many attempts were unsuccessful ([21] and reference 
therein). Preparations of inactivated BLV or crude 
lysates from persistently infected cell lines led to partial 
protection. Because this strategy has the intrinsic risk 
of transmitting infection, viral proteins, such as gp51 
surface envelope glycoprotein or p24 gag antigen, were 
tested for prophylactic immunization. These vaccines 
were immunogenic but did not consistently protect 
from BLV challenge. Similar conclusions were obtained 
with short peptides, possibly due to inadequate stere-
ochemical structure and partial epitope presentation 
[10]. Recombinant vaccinia viruses expressing BLV 
envelope glycoproteins conferred partial protection and 
reduced proviral loads in sheep but were unfortunately 
ineffective in cows. Finally, DNA vectors containing 
the ENV and TAX genes elicited a vigorous immune 
response but did not prevent later infection. As other 
previously developed immunogens, DNA vaccines were 
thus also disappointing.
In fact, available vaccines against retroviruses are 
extremely limited with a few marked exceptions (e.g. 
feline leukemia virus, FeLV). A major challenge in anti-
retroviral vaccination is that, once established, the virus 
cannot be cleared from the host. Therefore, only a pro-
phylactic vaccine providing sterilizing immunity repre-
sents a conceivable solution for BLV-infected animals. 
The criteria required to achieve this optimal vaccine 
are unknown but should in principle involve humoral, 
cytotoxic and perhaps innate immunity. The colostrum 
that the calf suckles soon after birth contains neutral-
izing anti-BLV antibodies that protect against a series 
of agents including BLV [10]. A strong humoral immu-
nity is nevertheless not sufficient to provide protection 
since vaccines eliciting high anti-BLV antibody titers 
are inefficient (reviewed in [22]). Unmet criteria such as 
the quality of the antiviral antibodies (i.e. neutralizing 
activity, conformation, isotype, avidity) likely explain 
failure of vaccines based on inactivated viral particles, 
crude lysates, purified antigens and peptides. The main 
limitations of these vaccines include the fast decline 
of protective antibody titers and poor stimulation of 
cytotoxic response. For still unclear reasons, eliciting 
both humoral and cell-mediated immunity may also 
be insufficient as illustrated by the inability of plasmid 
and recombinant vaccinia virus vectors expressing BLV 
antigens to protect against infection [10, 11, 23, 24].
Together, these failures to obtain an efficient vaccine 
indicate that protection against BLV infection requires 
stimulation of humoral and cytotoxic immunity at dif-
ferent levels: quantitative (e.g. antibody titers, number 
of CTLs) and qualitative (e.g.  type of epitope, neutral-
izing activity, persistence). We think that failures to 
obtain a vaccine result from the inadequate equilibrium 
between these parameters.
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An efficient vaccine against BLV is available
As would have said Thomas Edison, these numerous 
attempts were not failures but rather successful dis-
coveries of “not making a good vaccine”. Therefore, we 
reasoned that the vaccine eliciting the best antiviral 
response would be the virus itself. Our data indeed indi-
cated that it is extremely difficult, if not impossible, to 
infect a BLV-infected animal with another BLV strain [25, 
26]. Since the BLV sequence variability within an infected 
animal and among strains worldwide is very limited [27], 
antigenic drift should not be a major issue, as observed 
in HIV [28, 29]. The key issue then lies in finding the 
right combination of deletions and mutations that would 
inactivate the pathogenic activity of the attenuated vac-
cine without loosing immunogenicity. This quest took 
us some time (i.e. since 1993) and involved the synergy 
between two complementary teams interested in basic 
science and having veterinary expertise. We designed an 
approach based on a live-attenuated BLV strain harbor-
ing multiple deletions and mutations. The rationale was 
to delete pathogenic genes (i.e. the oncogenic drivers, 
such as TAX and G4 [30]) while maintaining a low level 
of infectivity. After a series of failures, we have identified 
a deleted BLV provirus that is infectious in cattle but rep-
licates at very low levels. Inoculation of this vaccine elic-
its a vigorous anti-BLV immune response comparable to 
that of a wild-type infection (manuscript in preparation 
and patent # WO2014/131844). The vaccine is currently 
used to vaccinate against BLV infection in commer-
cial herd settings. Besides efficacy, the major challenge 
is safety of the vaccine: transmission from cow-to-calf, 
recombination with endogenous viruses, milk and meat 
composition.
What are the issues of using an attenuated BLV 
vaccine?
The attenuated vaccine has been obtained by targeted 
mutations and deletions of an infectious BLV provirus. 
Therefore, it is possible that the vaccine strain undergoes 
genetic drift with reversion of inactivating mutations 
back to the wild type sequence. Another possibility is 
antigenic shift resulting from recombination with a wild 
type virus. These sequence diversifications are in fact 
not really problematic because the resulting strain would 
acquire a wild-type genotype. This situation is thus iden-
tical to a failure of vaccination. A more severe hazard is 
the acquisition of mutations that increase pathogenic-
ity such as N230E substitution of an envelope N-linked 
glycosylation site [31, 32]. Since this mutation has never 
been identified in any available sequence worldwide, 
we think that this scenario is unlikely. Perhaps the most 
significant hazard is recombination with another virus 
or host sequence. Since genes have been deleted in the 
BLV vaccine, additional sequences can indeed be pack-
aged into the virion, as observed in Rous Sarcoma virus 
[33]. Rare cases of recombination between the poliovirus 
vaccine and coinfecting enteroviruses led to reversion to 
a pathogenic state [34]. There are also concerns about 
possible activation of endogenous retroelements by the 
vaccine strain. Whether this potential risk is a hazard 
evolving into a threat will require large-scale vaccina-
tion trials. Ongoing experiments indicate that the vaccine 
does not undergo any genetic drift and/or shift (manu-
script in preparation). It should be mentioned that these 
recombination events occurred in cell cultures contain-
ing high virus titers. Therefore, the risk can be reduced 
by using GMP-purified DNA from safe plasmid vectors 
based for example on the ccd toxin/antitoxin system [35]. 
Because of production costs, we are presently favoring 
an approach based on a stable cell line carrying an inte-
grated vaccine. This cell system has the additional advan-
tage to be devoid of any vector sequence but should be 
carefully screened for contamination by any potential 
pathogens.
Another risk is spread of the attenuated vaccine to non-
infected animals in the herd, from the cow to their calf 
(e.g. secreted in milk) or from bull to heifer (i.e. semen). 
Ten years follow-up of uninfected sentinels did not reveal 
a single event of transmission during vaccination trials. 
Passive antibodies are nevertheless transmitted from the 
vaccinated cows to the newborn calves via the maternal 
colostrum. Although the mechanism is still unknown, 
it is likely that the attenuated virus is unable to spread 
because of limited replication capacity. Indeed, only ani-
mals with high proviral loads seem able to transmit BLV 
[36]. Current data indicate that the proviral loads of the 
attenuated vaccine even decrease progressively over 
time. Importantly, all vaccinated animals were protected 
against infection and therefore did not develop tumors.
Since BLV also infects other bovines (zebu, water buf-
falo) and can also be experimentally transmitted to 
sheep, goats or alpaca (Vicugna pacos), the impact of 
vaccination on other species should be considered. How 
might evolution of the virulent BLV strains be driven 
after widespread use of a BLV vaccine? Would the spread 
of the vaccine strain to wild animals cause any concern? 
What is the risk for recombination of the vaccine with 
wild type virus?
An additional issue that is possibly associated with an 
attenuated vaccine pertains to exhaustion. Could con-
tinuous viral expression at extremely low levels combined 
with a strong immune response be problematic? This 
mechanism would indeed lead to cell exhaustion in vac-
cinated animals. Notwithstanding, this issue is expected 
to be less tricky in vaccinated cows since the amount of 
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viral antigen is lower compared to animals infected with 
wild-type virus.
Is BLV zoonosis an issue? Although controversial, 
recent reports suggest that BLV may be associated 
with human cancer [16]. To be demonstrated, the link 
between BLV and human cancer would require further 
functional and epidemiological evidence. Only a few 
studies have investigated a possible link between dietary 
exposure to BLV and human cancer [37–40]. Contra-
dictory conclusions were drawn because these studies 
were not designed prospectively to specifically address 
the association between dairy consumption and can-
cer. The most striking functional evidence was provided 
by onset or erythroleukemia in chimpanzees fed with 
BLV-infected milk [41–43]. If the association is demon-
strated beyond correlation studies, the dilemma would 
be to choose between hazards linked to large-scale vac-
cination and a threat of breast cancer in regions where 
BLV is highly prevalent. Since vaccination is expected to 
reduce prevalence, elimination of BLV in cattle would be 
promoted. Our data also indicates that the vaccine is not 
present in milk and meat, suggesting that bovine-derived 
food would be less hazardous.
What are the lessons for HTLV vaccination?
Some aspects of vaccination against BLV may be instruc-
tive for the design of a vaccine against HTLV. Important 
questions relate to the type of vaccine, the target popula-
tion, the modes and the goals of vaccination.
At first glance, the option of an attenuated vaccine 
would not be considered because of potentials hazards 
that are not justified by expected gains. Indeed, a prob-
ability of 5% to develop disease, either tropical spas-
tic paraparesis/HTLV-associated myelopathy (HAM/
TSP) or Adult T-cell leukemia/lymphoma (ATLL), does 
not justify the risk. The failures of BLV vaccines based 
on purified proteins, peptides, inactivated antigens or 
recombinant vector vaccines indicate that the situa-
tion is more complex than expected. However, design of 
a vaccine against HTLV will nowadays benefit from the 
most recent developments in terms of vectorisation, anti-
gen selection, purification and combination with opti-
mal adjuvants. It should nevertheless be mentioned that 
inactivated or subunit vaccines are not devoid of risk as 
illustrated for FeLV [44] and other viruses [45]. Although 
still obscure, the mechanism involves antibody-depend-
ent enhancement of viral infection. A number of unsuc-
cessful trials in the BLV model further indicate that an 
efficient vaccine requires a subtle qualitative and quan-
titative equilibrium of humoral and cytotoxic immunity. 
These characteristics are clearly more difficult to fulfill 
for inactivated or subunit vaccines.
Should the HTLV vaccine be prophylactic, therapeutic 
or both? These options have their specific requirements 
and limitations. A large-scale preventive vaccination as 
we propose for BLV is probably not justified due to the 
low prevalence of HTLV in many regions worldwide. A 
cost/benefit evaluation should be undertaken to identify 
the target population. It is nevertheless predicted that 
prophylactic vaccination would be beneficial in endemic 
regions such as Australia or Japan [46]. Since colos-
trum antibodies protect against infection, should preg-
nant and/or breastfeeding mothers also be vaccinated? 
Besides, vaccination of children from HTLV-infected 
mothers may be impaired by colostrum intake, as we 
encountered in the BLV model. In this context, the age 
of vaccination may also be crucial because of a potential 
risk of autoimmunity. It would be interesting to address 
this mechanism upon BLV vaccination since immunity is 
still immature at birth in the bovine species.
As indicated earlier, only prophylaxis preventing infec-
tion is useful for BLV. For HTLV, therapeutic vaccines 
may boost antiviral response and improve disease out-
come by tempering morbidity of HAM/TSP and increas-
ing survival in ATLL. It remains nevertheless possible 
that vaccination with viral antigens such as TAX and 
HBZ would rather activate viral replication [47]. Other 
risks include antibody-dependent enhancement of viral 
replication. In this context, the BLV system could pro-
vide a model to address specific questions to advance 
in HTLV vaccine development, in particular safety risks 
(recombination with endogenous sequences, side effects, 
viral transmission and pathogenesis).
Conclusion
We have developed a vaccine against BLV using a strain 
that lost pathogenic potential while remaining sufficiently 
antigenic to induce lasting protective immunity. Obtain-
ing a vaccine providing sterilizing immunity has been a 
long story requiring bypass of a number of hurdles. The 
BLV paradigm has illustrated that vaccine development is 
possible and may be a model for viruses in other species 
(e.g. HTLV). Current efforts aim at making this vaccine 
available worldwide. After having bypassed most tech-
nical hurdles, the challenge is now to achieve industrial 
scale-up, local registration of the vaccine and approval by 
the end users. Perhaps the most important risk is the lack 
of interest of the industry that only focuses on high profit 
developments. This is unfortunately also true for a future 
HTLV vaccine.
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